Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review compiles current insights into alopecia areata's epidemiology, immune mechanisms, diagnosis, treatment options, including novel JAK inhibitors, and its severe psychosocial impact, while also highlighting emerging research areas.

This study describes and characterizes four cases of alopecia areata induced by immune checkpoint inhibitor therapy in cancer patients, highlighting the importance of recognizing and managing these hair-related adverse events.

In this case study, treatment with the selective JAK1 inhibitor upadacitinib significantly improved symptoms in a patient with refractory alopecia areata, vitiligo, ankylosing spondylitis, and allergic asthma-nasal syndrome, though a transient liver function abnormality was noted.

In this analysis, safety data from two clinical trials showed that baricitinib for severe alopecia areata had predictable side effects like infections and elevated CPK, with some serious adverse events noted at low incidence rates; no deaths were reported.

This case report describes a 5-year-old Akita with granulomatous sebaceous adenitis and pseudocyesis, who showed clinical remission and maintained a good quality of life after treatment with surgery and topical therapy.

This case report describes successful treatment of alopecia areata and atopic dermatitis in a pediatric patient using the Janus kinase 1 inhibitor upadacitinib, with significant hair growth improvements noted after six weeks.

In this study, pediatric and young adults with alopecia areata reported high satisfaction with oral Janus kinase inhibitors, decreased hair loss severity, and a willingness to continue treatment despite potential risks, citing improvements in hair regrowth, tolerability, quality of life, and mental health.

This study provides a comprehensive analysis of anabolic-androgenic steroids, reporting that their use enhances muscle mass but is associated with significant health issues including cardiac muscle hypertrophy, liver disease, and changes in gender characteristics, emphasizing the need for patient awareness of these risks.

This review discusses the potential of JAK inhibitors for treating alopecia areata and reports case study evidence of their effectiveness, but formal clinical trials are needed for more definitive conclusions.

This review discusses the role of Janus-kinase inhibitors in treating severe atopic dermatitis and alopecia areata, presenting case studies that show their efficacy and calling for further research on long-term effectiveness and safety.

This study found that their newly developed ADRL framework significantly improved the accuracy of scalp tissue layer segmentation in HR-MR images compared to existing methods.

In this review, researchers explore evidence showing that JAK inhibitors, particularly baricitinib and deuruxolitinib, are effective in promoting hair regrowth in severe alopecia areata while maintaining acceptable safety profiles, though long-term data remains scarce.

In this study, a 15-year-old male with alopecia areata universalis showed significant hair regrowth after an 8-month combination therapy, suggesting that comprehensive treatment, including antiviral, corticosteroid, and LED therapy, may be effective albeit long-term for managing this condition.

The man's hair loss and skin papules were diagnosed as atrichia with papular lesions, not alopecia areata universalis.

In this research, the authors reported that long-term treatment with the JAK1/JAK2 inhibitor baricitinib effectively maintains hair regrowth in patients with severe alopecia areata and may gradually improve outcomes for partial responders over 104 weeks, without increasing side effect incidence.

This article discusses barriers to obtaining JAK inhibitor therapy for patients with alopecia areata and highlights that racial inequities may worsen these difficulties; it calls for further advocacy to improve access.

This study observed that most pediatric patients with alopecia areata experienced some hair regrowth after treatment with topical JAK inhibitors, and the formulations were generally well-tolerated with mild lab abnormalities in some cases.

This case report describes a 5-year-old boy with acquired acrodermatitis enteropathica and normal serum zinc levels, improving clinically after zinc supplementation.

This study reports a case where a patient with rheumatoid arthritis and alopecia areata saw significant improvement in both conditions after switching to daily upadacitinib treatment, specifically achieving complete hair regrowth within six months.

In this retrospective study, researchers found that baricitinib was effective for treating moderate to severe alopecia areata, with response rates in 24 patients comparable to existing real-world data, and no new safety concerns were identified.

Hair loss treatment caused more hair loss in a man.

This study reviewed therapies for alopecia areata and suggests that Janus kinase inhibitors, such as baricitinib and upadacitinib, show promise in treating both alopecia areata and associated immune-mediated inflammatory diseases.

This case series observed that five Black pediatric patients with moderate to severe alopecia areata showed significant hair regrowth and minimal disease activity after treatment with topical JAK inhibitors, vitamin D supplementation, and antihistamines, with additional therapies in some cases.

This study reports that ritlecitinib, when used for up to 24 months in patients aged 12 and older with alopecia areata, has an acceptable safety profile, with a similar proportion of adverse events in both ritlecitinib and placebo groups in the placebo-controlled cohort.

This study reported that in a case series of three adolescents with alopecia areata and atopic dermatitis, treatment with 15 mg/day of upadacitinib led to rapid improvement in skin symptoms and significant hair regrowth over 12 months, with no severe adverse events observed.

This case report highlights two instances of alopecia areata, demonstrating diverse presentations, and suggests upadacitinib as a promising treatment option, resulting in hair regrowth within 3–6 months, without worsening sarcoidosis-related skin lesions.

This study found that adding allergen immunotherapy to conventional treatment may reduce relapse-related hair loss in house dust mite-allergic alopecia areata patients over a 3-year period.

In this case study, upadacitinib treatment for a patient with coexisting ulcerative colitis and alopecia universalis resulted in significant hair regrowth and maintained UC remission, suggesting potential for treating similar dual-diagnosed cases.

This study suggests that targeting mitophagy to regulate mitochondrial dysfunction and inhibit inflammasome activation could offer a novel therapeutic approach for alopecia areata.